Pitt St Research Report..., page-10

Possibly... coz it previously it had been described as "an adjuvant to be administered alongside other therapies". Prof Richard Scolyer's immunotherapy experiments carried out on his GBM cancer involved a neoadjuvant being administered before surgery and/or before radiation. One of the great findings there for him and the bio world is that the immunotherapy regime shows that they have been able to penetrate the blood-brain barrier and t-cells are seen to be proliferating in his brain.... and thus, able to their job!

Getting back to CellPryme, its obvious that the team are progressing it via third-party integration. PTX look to be having to convince such parties that they need to spend money to potentially save way more money in the longer term and, of course, potentially reap better efficacy results in trials. If we land service-providers (one of which could well be Thermo Fisher) CP could be home and hosed as a licensing platform.





CellPryme-A appears to have more regulatory hurdles to jump when looking at this (which could be the "interesting findings"):-

Its all looking promising, albeit on a longer timeline than expected. Afterall, it was CellPryme that Bec stated as being "close to our heart" in the TF webinar on OmniCAR. Far closer to a licensing deal with some recent optimisation results which have really boosted its effectiveness. If clincial trials incorporating CellPryme-M do well, further CP-M deals should follow and CP-A to will likely be easier to license in due time.